Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population‐based cohort study
Cancer Medicine · 2023
DOI: 10.1002/cam4.6344 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yan Hiu Athena Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardio-oncology Research Unit, Cardiovascular Analytics Group, PowerHealth Limited, Hong Kong, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Objective
This population‐based study examined the association between baseline uric acid (UA) and prostate cancer (PCa)‐related mortality amongst PCa patients receiving androgen deprivation therapy (ADT).
Methods
Adults with PCa who received ADT in Hong Kong between December 1999 and March 2021 were identified. Patients with missing baseline UA were excluded. Patients were followed up until September 2021. The outcome was PCa‐related mortality.
Results
Altogether, 4126 patients (median follow‐up 3.1[interquartile range 1.4–6.0] years) were included. A J‐shaped association was observed between baseline UA level and PCa‐related mortality risk, with a direct association in those with mean(0.401 mmol/L) or above‐mean baseline UA levels (hazard ratio (HR) per standard deviation‐increase 1.35 [95% confidence interval 1.21,1.51], p < 0.001), and an inverse association in those with below‐mean baseline UA levels (HR 0.78[0.67,0.92], p = 0.003). The former remained significant on competing risk regression, but not the latter.
Conclusions
A J‐shaped relationship between baseline UA level and PCa‐related mortality risk was identified. This study was mainly limited by potential unmeasured and residual confounders. Further validation studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardio-oncology Research Unit, Cardiovascular Analytics Group, PowerHealth Limited, Hong Kong, China.
- SH Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
- Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
- Kent and Medway Medical School, Canterbury, Kent, UK.
ORCID-Profile: Yan Hiu Athena Lee, Jeffrey Shi Kai Chan, Jeremy Man Ho Hui, Edward Christopher Dee, Tong Liu
Förderung
- NCI NIH HHS
Zitieren
APA
Lee, Y. H. A., Chan, J. S. K., Leung, C. H., Hui, J. M. H., Dee, E. C., Ng, K., Liu, K., Liu, T., Tse, G., & Ng, C. F. (2023). Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population‐based cohort study. Cancer Medicine. https://doi.org/10.1002/cam4.6344
Vancouver
Lee YHA, Chan JSK, Leung CH, Hui JMH, Dee EC, Ng K, et al. Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population‐based cohort study. Cancer Medicine. 2023. doi:10.1002/cam4.6344
BibTeX
@article{Lee2023,
author = {Lee, Yan Hiu Athena and Chan, Jeffrey Shi Kai and Leung, Chi Ho and Hui, Jeremy Man Ho and Dee, Edward Christopher and Ng, Kenrick and Liu, Kang and Liu, Tong and Tse, Gary and Ng, Chi Fai},
title = {Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population‐based cohort study},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6344}
}
EUVIMED